SCHEMBL3777797

SCHEMBL3777797

COC(=O)COc1ccc(F)c2nc(OC(F)F)c(Cc3ccc(Cl)cc3Cl)c(C)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
PTGDR2 Q9Y5Y4 2/20 0.38
PTGDR Q13258 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
KDM4E B2RXH2 2/20 0.36
GAA P10253 1/20 0.36
TSHR P16473 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
F2 P00734 1/20 0.35
LMNA P02545 2/20 0.35
HTT P42858 2/20 0.35
LPAR2 Q9HBW0 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
KCNJ6 P48051 1/20 0.35
KCNJ5 P48544 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3772456 0.94 ALDH1A1 (0.40) MAPTKMT2AMEN1PTGDR2PTGDR
SCHEMBL3777688 0.94 PTGDR2 (0.39) MAPTKMT2APTGDR2PTGDRKDM4E
SCHEMBL3784139 0.91 TDP1 (0.44) MAPTKMT2AMEN1PTGDR2PTGDR
SCHEMBL3777981 0.90 TSHR (0.37) PTGDR2L3MBTL1GAATSHRLMNA
SCHEMBL3786950 0.88 ALDH1A1 (0.36) MAPTPTGDR2KDM4ELMNAALDH1A1
SCHEMBL3783447 0.88 PTGDR2 (0.43) PTGDR2PTGDR
SCHEMBL3782942 0.87 MEN1 (0.39) MAPTKMT2AMEN1L3MBTL1KDM4E
SCHEMBL3776466 0.87 MEN1 (0.39) MAPTKMT2AMEN1L3MBTL1KDM4E
SCHEMBL3776116 0.87 MEN1 (0.39) MAPTKMT2AMEN1L3MBTL1KDM4E
SCHEMBL3778028 0.85 PTGDR2 (0.41) PTGDR2TSHRTDP1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 MAPT 4787/4885KMT2A 3406/4885MEN1 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.